Scientists have developed new therapeutic molecules that may reverse memory loss linked to depression and ageing.
The molecules were invented by scientists at Toronto’s Centre for Addiction and Mental Health (CAMH) to treat cognitive symptoms such as memory loss that occur in depression, ageing, and other mental illnesses.
A dosage of these molecules was administered in pre-clinical models of stress-induced memory loss, and 30 minutes later, memory performance returned to normal levels.
The experiment was repeated more than 15 times to confirm results.
The scientists also administered molecules on aged pre-clinical models. After administration, memory declines were rapidly reversed and performance increased to 80 percent, essentially reaching levels seen in youth or earlier stages of adulthood.
“The aged cells regrew to appear the same as young brain cells, showing that our novel molecules can modify the brain in addition to improving symptoms,” said Etienne Sibille, lead researcher of the study.
“We’ve shown that our molecules enter the brain, are safe, activate the target cells and reverse the cognitive deficit of memory loss.”
Sibille added that plans are underway to start clinical testing for the new molecules in two years.
A success in the clinical testing will open a doorway of medical opportunities in treating cognitive deficits in mental illness.
It will also be significant in the treatment of memory loss, especially at the beginning stage of Alzheimer’s disease.